Search results
Results from the WOW.Com Content Network
Prior to studying medicine, Robert Malone studied computer science at Santa Barbara City College for two years, acting as a teaching assistant in 1981. [2] [8] He received his BS in biochemistry from the University of California, Davis in 1984, his MS in biology from the University of California, San Diego in 1988, and his MD from Northwestern University Feinberg School of Medicine in 1991.
Drew Weissman (born September 7, 1959) is an American physician and immunologist known for his contributions to RNA biology. Weissman is the inaugural Roberts Family Professor in Vaccine Research, director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).
Hoerr did experimental research on the stabilization of messenger ribonucleic acid (mRNA). In 1999, he received his PhD from Günther Jung, Institute of Organic Chemistry, in cooperation with Hans-Georg Rammensee, Institute of Immunology and Cell Biology (both: University of Tübingen) on the topic of RNA vaccines for the induction of specific cytotoxic T lymphocytes (CTL) and antibodies.
Two pioneering scientists who created the technology behind life-saving Covid-19 vaccines have won the Nobel Prize in medicine or physiology.
While an employee of the NIH, Venter learned how to identify mRNA and began to learn more about those expressed in the human brain. The short cDNA sequence fragments Venter discovered by automated DNA sequencing, he named expressed sequence tags, or ESTs. The NIH Office of Technology Transfer decided to file a patent on the ESTs discovered by ...
The two-dose vaccine employs the same messenger RNA (mRNA)technology used in the COVID-19 shots developed by Pfizer with BioNTech, and by Moderna. It delivers tiny lipid particles containing mRNA ...
Kary Banks Mullis (December 28, 1944 – August 7, 2019) was an American biochemist.In recognition of his role in the invention of the polymerase chain reaction (PCR) technique, he shared the 1993 Nobel Prize in Chemistry with Michael Smith [2] and was awarded the Japan Prize in the same year.
Ever since, mRNA-based therapy has been Karikó's primary research interest. However, in the 1990s, mRNA fell out of favor as many researchers, biotechs, and pharmaceutical companies doubted its potential. Though supported by Elliot Barnathan (who left UPenn in 1997) and David Langer (who then hired her), Karikó found it difficult to gain funding.